Navigation Links
Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
Date:9/8/2008


- These funds will be used to rapidly implement the first phase of the

production capacity and productivity expansion in order to meet

strongly increasing customer demand-

- No more concerns about raising additional capital now-

- The Company has decided not to proceed with the private placement of

the previously announced convertible debentures at present market

conditions-

LAVAL, Quebec, Sept. 8 /PRNewswire-FirstCall/ - Neptune Technologies & Bioressources Inc. (NASDAQ.NEPT - TSX.V.NTB) announced today that it has entered into a new financing arrangement with Desjardins Group, which will provide the Company with up to $8.5 million in financing. The Company expects the funds to used to improve productivity and increase production capacity in order to meet the currently rapidly growing demand for its products.

Of the financing, $3 million is earmarked to purchase customized equipment to optimize the extraction process and to increase productivity and production capacity with a target of reaching 120 000 kg of Neptune Krill Oil (NKO(R)) production per year, doubling current capacity. Another $3.5 million of the financing will be allocated to refinance the long term debt of the Company at a lower annual interest rate of 7.71%. This refinancing of long term debt will allow the Company to save more than 2.5% of its interest charge and improve next year's cash flow. Finally, a line of credit initially of $1 million, which can be increased to $2 million, has also been established. Investissement Quebec participated in this financing by guaranteeing up to 38% of the financing, excluding the line of credit. "Obtaining better financing conditions, particularly in the context of the current credit environment, constitutes a validation of our financial strength and of our business plan," commented Xavier Harland, Director of Finance.

"This expansion of our capacity is crucial to meeting actual and forecasted strongly increasing customer demand for our products with our plant presently running at full capacity. Now we have the financial resources to quickly implement the first phase of our capacity expansion program and the financing provides the Company with adequate financial resources to eliminate any pressure for raising additional capital such as the convertible debentures under current market conditions," stated Andre Godin, VP, Finance and Administration of Neptune.

"Since Neptune maintains its position for the minimum conversion price which is over $2, the Company has decided in agreement with its U.S. investment banker that given current market conditions, it would not be advantageous to the Company or in the best interest of our existing shareholders to proceed with the previously announced private placement of convertible debentures at this time," he added. "If funds are required for any future needs, Neptune has other options with better conditions to explore in due course, and now, with the bank financing concluded for the plant expansion, we have eliminated any previous concerns about capital needed," Mr. Godin continued.

The second phase of the capacity expansion program is expected to be realized through a partnership with a worldwide leading industrial manufacturing company conforming to nutraceutical and pharmaceutical Good Manufacturing Practice (GMP) standards with the mandate to offer substantially larger capacity within two years. This will allow the Company to respond to the growing demands of its dietary supplement and functional food customers as well as pharmaceutical customers and strategic partners.

About Neptune Technologies

Neptune researches and develops proprietary bioactive ingredients and products for nutraceutical and pharmaceutical applications and is sponsoring clinical research to demonstrate the therapeutic benefits in various medical indications. The Company patents its intellectual property, protects its industrial secrets and innovations and continuously expands its intellectual property portfolio. Neptune has already obtained many regulatory approvals allowing commercialization of its products in various geographic markets and has filed for and is expecting additional approvals. Neptune continues to strongly support its strategic development plan to form partnerships with worldwide leaders in the nutraceutical industries. Neptune has signed agreements with Nestle and Yoplait, worldwide leading food manufacturers, and paved its entrance into the global functional food market.

Neither NASDAQ nor TSX venture exchange accepts responsibility for the

adequacy or accuracy of this press release.

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.


'/>"/>
SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results
2. Neptune Technologies & Bioressources Inc. Reports First Quarter Results and Business Update
3. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
4. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
5. Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
6. Neptune Technologies receives GRAS notification in the United States
7. Neptune Technologies expands into medicinal markets in Asia Pacific
8. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
9. The Omega-3 Industry Leader, Croda Health Care, selects Neptune Technologies Ingredients for New Essentially Brand
10. Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones
11. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... Yorba Linda, Ca (PRWEB) , ... May 25, ... ... a number of Terumo BCT case studies, describing how process development ... learn from new results of T-cell expansion using a hollow-fiber bioreactor system, along ...
(Date:5/24/2017)... WEST BOUNTIFUL, Utah (PRWEB) , ... May 24, ... ... announces the selection and implementation of CLEARAS Water Recovery’s Advanced Biological Nutrient ... is a key component of a $24 million plant upgrade to sustainably meet ...
(Date:5/24/2017)... , May 23, 2017 As Ebola resurfaces in ... four deaths and 20 suspected cases now reported, a new ... PubMed database, showed a correlation between the 2014 and 2017 ... counts rose sharply in 2012-13, which preceded the 2014 outbreak. ... the Ebola gene Replikin counts in 2014-15, which again precedes ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... month its 20th anniversary, marking the occasion with a strong presence at Bio-IT ... Welcome Reception and further extends an invitation to all attendees to view ...
Breaking Biology Technology:
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... & Trends - Industry Forecast to 2025" report to their ... The Global ... CAGR of around 15.1% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
(Date:3/22/2017)... , March 21, 2017   Neurotechnology , ... recognition technologies, today announced the release of the ... which provides improved facial recognition using up to ... a single computer. The new version uses deep ... accuracy, and it utilizes a Graphing Processing Unit ...
Breaking Biology News(10 mins):